Skip to content

Author

Nima Rezaei

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Immune checkpoint inhibitor-induced diabetes mellitus: A review of mechanisms, clinical features, and therapeutic approaches.

Since the FDA approval of ipilimumab in 2011, immune checkpoint inhibitors (ICIs) have reshaped the paradigm of cancer treatments. This has been pursued with the development and clinical investigation of combination immunotherapies with multiple ICIs. However, more than 20% of recipients of ICI monotherapy and a higher...

Mohammad Parsapour, Pouya Mahdavi Sharif, Nima Rezaei · 0 citations
Open access Nov 2026

A Large Multicenter Cohort of Ataxia–Telangiectasia: Clinical, Immunologic, Genetic, and Survival Outcomes

ABSTRACT Background Ataxia telangiectasia (AT) is a life‐threatening multisystem disorder characterized mainly by neurologic manifestations, infections, and malignancy. We aimed to present a comprehensive analysis of demographic, clinical, immunologic, and genetic features and outcomes of patients with AT in Iran. Meth...

Saba Fekrvand, A. Firouzabadi, Pouya Vakilipour et al. · 0 citations
Review Aug 2026

Senescence-Associated Mitochondrial Dysfunction as a Therapeutic Target in Ovarian Cancer: Challenges and Opportunities.

Senescence-associated mitochondrial dysfunction (SAMD) links aging, metabolic reprogramming, and therapy resistance in ovarian cancer. Persistent damage to mitochondrial DNA (mtDNA), impaired mitochondrial quality control, and disrupted mitochondrial fusion and fission dynamics compromise electron transport (ET) and me...

H. Khalili, Banafshe Abadi, Nima Rezaei · 0 citations
Review Open access Sep 2026

Triazole‐ and Imidazole‐Containing Compounds: Versatile VEGFR‐2 Inhibitors for Cancer Therapy

This review compiles in vitro, in vivo, and in silico data on triazole‐ and imidazole‐based VEGFR‐2 inhibitors, providing a basis for understanding trends relevant to the design and development of optimized anti‐angiogenic agents.

Parisa Nikfar, Mina Hosseini, Nima Rezaei et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.